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Introduction
Gastric cancer is one of the most common malignant tumors in Japan. The development of adjuvant chemotherapies has improved clinical outcome to a certain extent; however, advanced gastric cancer with lymph node metastasis still has a poor prognosis (1, 2) . A number of genes appear to contribute to the malignant potential of gastric cancer (3, 4) . However, the identification of the precise factors which predict the prognosis and recurrence of gastric cancer remains extremely important.
MiRNAs are 20-to-25 mer non-coding RNAs which incompletely bind to the 3'UTR of multiple target mRNAs, enhancing their degradation and inhibiting their translation.
MiRNAs possess normal biological functions, such as regulation of proliferation, differentiation and apoptosis. Moreover, dysregulated of miRNAs play critical roles during carcinogenesis and cancer progression (5, 6) . The levels of many miRNAs in cancer tissue are lower than those in normal tissue, a state which contributes to cancer progression (7). miR-146a in gastric cancer PI3K-PDK1-Akt, and RalGDS (9, 10) . IRAK1 is upstream of NF-κB and is involved in cancer progression (8, 11, 12) . Moreover, EGFR activates NF-κB by phosphorylation of IκB (13) . Therefore, we have focused on the relationship between miR-146a and its target genes, both EGFR and IRAK1.
Previous reports indicated that miR-146a inhibits progression of solid tumors derived from cancer cell lines, but there are no reports about the function and significance of miR-146a at the clinical level (8, [14] [15] [16] .
The level of miR-146a is regulated by a single nucleotide polymorphism (SNP). This G/C SNP (rs2910164) is located within the seed sequence of pre-miR-146a, which is the miR-146a precursor. It resides in the passenger strand of miR-146a (miR-146a*). G/C SNP regulates the level of mature miR-146a in thyroid cancer, prostate cancer, hepatocellular carcinoma and familial breast / ovarian cancer (12, (16) (17) (18) (19) . Furthermore, G/C SNP is associated with the risk of carcinogenesis in these cancers.
In the current study, we demonstrated the clinical significance of miR-146a as a tumor suppressor in gastric cancer cases and analyzed the function of miR-146a in gastric cancer cells. Moreover, we examined the G/C SNP by direct sequencing of genomic DNA from 76 patients. We then compared the expression levels of miR-146a in gastric cancer tissue (T) and corresponding noncancerous tissue (N) to determine 
Materials and Methods
Clinical samples Ninety gastric cancer samples were obtained during surgery and used after obtaining informed consent. All patients underwent curative resection of the primary tumor at Kyushu University Hospital at Beppu between 1992 and 2000. All patients had a clear histological diagnosis of gastric cancer, based on the clinicopathologic criteria described by the Japanese gastric cancer association (20). All patients were closely followed after surgery at regular three-month intervals. The follow-up periods ranged from two months to 11 years, with a mean of three years. All data, including age, sex, histological grade, tumor size, depth (T factor), lymph node metastasis (N factor), lymphatic invasion, venous invasion, liver metastasis, and peritoneal dissemination were obtained from clinical and pathologic records. No patients received neoadjuvant chemotherapy or radiotherapy before surgery and adjuvant radiotherapy after surgery. 47 patients received adjuvant chemotherapy after surgery. Resected cancerous tissues (T) and paired noncancerous tissues (N) were immediately cut and stored in RNAlater (Ambion), frozen in liquid nitrogen, and kept at -80 °C until RNA extraction. RNA was extracted using ISOGEN (NipponGene) according to the manufacturer's protocol.
Research. miR-146a in gastric cancer detected using primary antibodies, EGFR and IRAK1 antibody (Santa Cruz Biotechnology) diluted 1:500 and then primary antibodies were detected using HRP-conjugated secondary antibodies (GE Healthcare). EGFR and IRAK1 proteins were normalized to the level of β-actin protein (Cytoskeleton, Inc.) diluted 1:1000.
DNA isolation and genotyping Genomic DNAs were extracted from 76 gastric cancer tissues using the QIAamp DNA mini kit according to the manufacturer's protocol (Qiagen), followed by direct DNA sequencing. A 227 bp fragment containing the pre-miR-146a region and polymorphism site (rs2910164) was amplified using the following primers: 5' -ATTTTACAGGGCTGGGACAG-3' and 5' -TCTTCCAAGCTCTTCAGCAG-3'. The PCR products were electrophoresed on agarose gels and purified with ethanol precipitation. Purified PCR products were sequenced using a Big-Dye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems) and an ABI3130x Genetic Analyzer (Applied Biosystems). 
Invasion and migration assay
Construction of reporter plasmids and luciferase reporter assay
To construct a luciferase reporter plasmid, an EGFR or IRAK1 -3'UTR full length fragment was subcloned into pmirGlo Dual-luciferase miRNA Target Expression Table 2 ).
MiR-146a inhibits the migration and invasion of gastric cancer cells
Because lower miR-146a levels were associated with the T factor, lymph node metastasis (N factor) and venous invasion, we evaluated miR-146a function in gastric cancer cells. We transfected miR-146a into the gastric cancer cell line, MKN45, followed by assays conducted under conditions of serum starvation. Expression of miR-146a significantly inhibited the cell's capability for migration and invasion compared with control cells (P = 0.012, P = 0.017; Student's t test; Figure. 
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Discussion
This study demonstrated that miR-146a levels in cancerous tissue (T) were significantly lower than those in noncancerous tissue (N) in gastric cancer patients.
Moreover, the miR-146a level was associated with the lymph node metastasis (N factor) and venous invasion. In addition, a lower level of miR-146a expression was a strong independent prognostic factor. Based on array data, it was previously reported that a combination of several miRNAs may be useful as prognostic markers in gastric cancer miR-146a in gastric cancer correlation between miR-146a levels and clinicopathologic factors, such as lymph node metastasis (N factor), and venous invasion. Moreover, we analyzed the recurrent pattern according to miR-146a levels in gastric cancer patients. MiR-146a low expression group showed the higher incidence of lymph node recurrence or peritoneal recurrence, not distant recurrence, compared to high expression group (Supplementary Table 1 ). In general, most gastric cancer develops more lymphatic metastasis than hematogenous metastasis. This study indicated that the reduced expression of miR-146a might play a role in gastric cancer progression through lymph node metastasis and peritoneal dissemination by inhibition of EGFR and IRAK1. Next, we validated that miR-146a binds to the EGFR or IRAK1 3'UTR and suppresses expression of these genes. In particular, molecular therapies targeted against EGFR increase the impact of treatment in breast and colorectal cancer patients (26, 27). Recently it was shown that therapy targeted against EGFR had a beneficial effect on gastric cancer patients in clinical trials (28, 29) . IRAK1 and subsequent NF-κB activation is associated with poor prognosis and invasion in gastric cancer (30, 31) . Because EGFR activates not only Raf-MEK-ERK and PI3K-PDK1-Akt signaling but also NF-κB by phosphorylation of IκB (13), EGFR-targeted therapy using miRNA could be a promising treatment in gastric cancer. 
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It is well known that the G/C SNP within the pre-miR-146a seed sequence changes miR-146a expression levels in several cancers (12, (16) (17) (18) (19) . We analyzed the G/C SNP of 76 gastric cancer patients by direct sequencing and found that miR-146a expression levels in patients with GG genotypes were significantly lower than those with CC genotypes, in both cancerous and noncancerous tissues. Therefore, this SNP may be associated with miR-146a levels in gastric cancer tissue. Shen et al. reported that the G allele was associated with lower miR-146a levels than was the C allele in the breast cancer cell line MCF-7 (18). In contrast, Xu et al. reported that the C allele was associated with lower miR-146a levels than the G allele in prostate cancer patients (16) .
These allele-dependent differences in miR-146a levels have been explained by differences in the splicing mechanism between U-G and U-C pairs in the stem region of pre-miR-146a and the subsequent impact on the generation of miRNA (32) . However, the detailed molecular mechanisms are not clearly clarified. This is the first report to analyze the significance of miR-146a in gastric cancer cases.
Moreover, we showed that the G/C SNP of the pre-miR-146a seed sequence regulates mature miR-146a levels. For this reason, we hypothesize that miR-146a levels could be estimated by analysis of the G/C SNP in peripheral blood. MiR-146a may play a critical role and prove useful as a novel prognostic marker and therapeutic tool. 
